Take the first step in your myasthenia gravis (MG) care and find out if MINT is right for you.
How could participating in the MINT study help further the knowledge of MG?
By participating in MINT, you may receive an investigational drug (called inebilizumab) designed to target the source of MG. Inebilizumab is an approved product for neuromyelitis optica spectrum disorder (NMOSD) in the U.S. and Japan but is investigational for MG. Safety and efficacy have not been established for MG.
Who can take part in the MINT study?
You may qualify for the MINT study if you meet the following requirements:
- You have an MG diagnosis
- You have MG affecting multiple muscle groups in the body
- You are receiving steroids, a non-steroid immunosuppressive treatment, or a combination of the two
Important: Other requirements will apply.
Note: If you meet the above criteria, you may qualify. Take the short pre-screener to see if you pre-qualify for the MINT study by clicking the button below.
What will happen during the study?
If you choose to participate, you will be assigned to one of two groups depending on the cause of your MG: Group 1 (AChR) or Group 2 (MuSK). You can expect the following:
- Visit the study clinic to find out if you qualify for the MINT study
- Attend study clinic visits for about 12 (Group 1) or 6 (Group 2) months
- Receive either two or three doses of inebilizumab or placebo (no active ingredients) by infusion
- Reduce steroid dosage (if applicable) starting four weeks after your first dose of inebilizumab or placebo
- Optional: You may stay in the MINT study for an additional 18-month extension. All participants will receive up to three doses of inebilizumab during this time